Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- Central Nervous System
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 305651
Licensor is a pharmaceutical company with a focus in CNS (central nervous system), Dermatology, and Pediatrics.
IPSCIO Record ID: 377097
VRP324 is a drug product candidate based on nanotechnology which enables the delivery of CBD into the brain via intranasal delivery for the management of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older, as well as patients one year of age and older who experience seizures associated with Lennox-Gastaut syndrome ( LGS) or Dravet syndrome. VRP324 is manufactured using high pressure homogenization and spray drying. In animal studies, the MET nanoparticles are well-tolerated via the nasal route at the dose administered.
Field of use is for the treatment of seizures associated with tuberous sclerosis complex (TSC) Lennox-Gastaut syndrome and Dravet syndrome in patients one year of age and older.
Lennox-Gastaut syndrome and Dravet syndrome are rare central nervous system diseases considered serious epileptic encephalopathies that cause different types of epileptic seizures as well as cognitive and behavioral changes and are generally resistant to treatment.
Tuberous sclerosis complex (TSC) is a hereditary condition associated with changes in the skin, brain, kidney, and heart. Seizures are a frequent complication, and some people with TSC have learning disabilities. Skin changes are the most noticeable sign of TSC and appear in nearly all people with the condition.
IPSCIO Record ID: 215874
IPSCIO Record ID: 25926
IPSCIO Record ID: 303746
Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.
Licensee is a biopharmaceutical company committed to developing treatments for psychiatric disorders.
IPSCIO Record ID: 369272
In order to establish a period of exclusivity for Licensee, University hereby agrees that it shall not grant any other license to make, have made, use, lease and sell the Patent Rights during the period of time commencing with the Effective Date of this Agreement and terminating with the full end of the term of this Agreement, unless sooner terminated as hereinafter provided.
Licensee shall have the right to sublicense worldwide any of the rights, privileges and license granted hereunder.
5,616,707 – Compounds which are useful for prevention and treatment of central nervous system disorders
5,726,316 – Pharmaceutical compositions for prevention and treatment of central nervous system disorders
Field of use is for nicotinic compounds for use in therapeutic applications, including for prevention and treatment of central nervous system disorders.